Increased mRNA levels of BTG1 and SLA in T cells, together with decreased expression of HLA- I molecules in tumor cells, suggest that FTD treatment might dampen T cell-mediated antitumor responses both by facilitating tumor immune escape and by reducing proliferation capacity and TCR signaling in T cells. Here, BTG1 is linked to frontotemporal dementia.